Europe
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Motif Bio plc announced that the Company has received the official minutes of the Type B meeting with the U.S. Food & Drug Administration which took place on September 19, 2019..
New DAS organization within cluster reflects changes in health ecosystem and integrates techno-therapies
Biocon Biologics in-licenses an early-stage biosimilar asset, will undertake development, manufacturing and commercialization under its own label
Early symptoms of frontotemporal dementia are often confused with symptoms occurring in psychiatric disorders.
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces an update on progress in its Phase IIa clinical study.
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period July 2019 to September 2019.
The largest study of its kind into childhood developmental disorders has discovered that jumping genes cause genetic changes in some patients with undiagnosed neurodevelopmental diseases.
Clinigen Group plc has launched a Managed Access Program for Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, to provide AZEDRA® via a global Managed Access Program, outside the United States.
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
PRESS RELEASES